Boomers Should Not ...
Health Care: Drugs
Salix Pharmaceuticals Ltd. (SLXP: NASDAQ)
$59.47 0.14 | 0.24%
05/22/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 64.25M | 87.40M | -27.06M | -43.62M |
| Operating Gains/Losses | 13.08M | 534.00K | -59.00K | -4.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -154.70M | -60.43M | -32.12M | -66.92M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 22.43M | 55.33M | -11.78M | 32.72M |
| (Decrease) Increase In Other Current Liabilities | 42.31M | 37.24M | 28.50M | -1.99M |
| (Increase) Decrease In Other Working Capital | 0.00 | 27.00M | 0.00 | 0.00 |
| Other Non-Cash Items | 23.88M | 15.79M | 44.60M | 6.44M |
| Net Cash From Continuing Operations | 87.59M | 119.15M | 25.52M | -56.34M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 87.59M | 119.15M | 25.52M | -56.34M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -5.37M | -26.14M | -5.57M | -12.13M |
| Acquisitions | -10.00M | -362.48M | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 15.00M | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -15.37M | -388.62M | 9.43M | -12.13M |
| Issuance of Debt | 690.00M | 0.00 | 345.00M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | -59.45M | 5.40M | -27.21M | 142.06M |
| Repayment of Long-Term Debt | -138.00K | -272.00K | -15.00M | -981.00K |
| Repurchase of Capital Stock | -74.82M | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -169.96M | 39.24M | -12.22M | -252.00K |
| Net Cash From Financing Activities | 385.62M | 44.37M | 290.57M | 140.82M |
| Effect of Exchange Rate Changes | 349.00K | -111.00K | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 458.19M | -225.22M | 325.52M | 72.36M |
Portfolios with SLXP
- Portfolio NameUser Type
- ContributorDrugs Facing FDA Approval i...
- User7 Stocks with Strong and St...
- ContributorBreakout Stocks Of The Week...
- ProDiscovery Capital Management
- ContributorBreakout Stocks Of The Week...
- Contributor10 Pharma Stocks With Upside
- Contributor10 Biotech Stocks Facing FD...
- UserTop Healthcare Short Squeez...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
Latest SLXP Headlines from TheStreet
- Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP) 01.28.13 | 04:01 am
- FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs 11.12.12 | 10:11 am
- Salix Pharmaceuticals Ltd. Stock Downgraded (SLXP) 11.09.12 | 04:11 am
- Nektar Therapeutics Is a Short 09.12.12 | 07:09 am
- Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Laggard 08.27.12 | 05:08 pm
- Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.10.12 | 07:08 pm
- 7 Most Reliable Growth Stocks in the Market 08.03.12 | 07:08 am
- Stocks Take Breather After Recent Surge 07.30.12 | 04:07 pm
- Salix Stock Hits New 52-Week High (SLXP) 07.02.12 | 09:07 am
- Salix Reaches New 52-Week High (SLXP) 06.19.12 | 10:06 am
Press Releases for SLXP
- Salix Pharmaceuticals Commits $1.125M To AGA Research Foundation - PR Newswire 03.13.13 | 09:03 am
- Salix Pharmaceuticals Reports 4Q2012 And FY2012 Results - Business Wire 02.28.13 | 04:02 pm
- Salix Pharmaceuticals To Present At Two Investment Conferences In March - Business Wire 02.25.13 | 01:02 pm
- Salix Pharmaceuticals Announces 4Q2012 And FY2012 Financial Results Conference Call And Webcast - Business Wire 02.14.13 | 07:02 am
- FDA Approves Fulyzaq™ (Crofelemer) 125 Mg Delayed-Release Tablets For The Symptomatic Relief Of Diarrhea In Patients With HIV/AIDS On Anti-Retroviral Therapy (ART) - Business Wire 01.02.13 | 07:01 am
- Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference - Business Wire 01.02.13 | 07:01 am
- Salix Pharmaceuticals Previews The American Association For The Study Of Liver Diseases 2012 - Business Wire 11.09.12 | 07:11 am
- Salix Pharmaceuticals Reports 3Q2012 Results - Business Wire 11.07.12 | 04:11 pm
- Salix Pharmaceuticals To Present At Two Investment Conferences In November - Business Wire 11.07.12 | 07:11 am
- Salix Pharmaceuticals Announces 3Q2012 Financial Results Conference Call And Webcast - Business Wire 10.24.12 | 07:10 am
Partner Headlines for SLXP
- Another Delay for Salix Candidate - Analyst Blog - NASDAQ 09.10.12 | 10:09 pm
- Another Delay for Salix Candidate - Analyst Blog - Zacks 09.10.12 | 06:09 pm
- Salix Pharma at Neutral - Analyst Blog - NASDAQ 08.21.12 | 09:08 pm
- Stocks Turn Mixed; Dillard's Breaks Out - Investor's Business Daily 08.09.12 | 11:08 am
- Futures Mixed On Jobs Data; Elizabeth Arden Spikes - Investor's Business Daily 08.09.12 | 09:08 am
- Stocks Extend Gains; Priceline.com Slides After Hours - Investor's Business Daily 08.07.12 | 05:08 pm
- Apple, Other Leaders Shaping Bases In Wild Market - Investor's Business Daily 08.03.12 | 06:08 pm
- Stocks Dip In Lower Volume; Cirrus Logic Soars After Hours - Investor's Business Daily 07.30.12 | 04:07 pm
- Stocks Down In Lower Volume; Salix Pharma Hammered - Investor's Business Daily 07.30.12 | 03:07 pm
- Stock Futures Mixed; Salix, Progenics Tumble - Investor's Business Daily 07.30.12 | 09:07 am
